Impact News +++ EFG International: Starkes Neugeldwachstum, aber Gewinn und Kernkapitalquote enttäuschen (Investing.com DE) +++ EFG INTERNATIONAL Aktie -5,50%

BRISTOL-MYERS Aktie

>BRISTOL-MYERS Aktienkurs

50.98 EUR +0.1% (TradegateBSX)

Ask: 51.14 EUR / 330 Stück

Bid: 50.91 EUR / 400 Stück

Tagesumsatz: 565 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>BRISTOL-MYERS Performance

1 Woche: -0,5%

1 Monat: +6,2%

3 Monate: +25,2%

6 Monate: +22,5%

1 Jahr: -0,4%

laufendes Jahr: +10,3%

>BRISTOL-MYERS Aktie

Name:

BRISTOL-MYERS SQUIBBDL-10

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US1101221083 / 850501

Symbol/ Ticker:

BRM (Frankfurt) / BMY (NYSE)

Kürzel:

FRA:BRM, ETR:BRM, BRM:GR, NYSE:BMY

Index:

S&P500

Webseite:

https://www.bms.com/

Profil:

Bristol-Myers Squibb Company is a leading biopharmaceutical firm engaged in the discovery, development, licensing, manufacture, marketing, distribution, and sale of innovative medicines worldwide. It ..
>Volltext..

Marktkapitalisierung:

104543.56 Mio. EUR

Unternehmenswert:

135665.59 Mio. EUR

Umsatz:

40732.09 Mio. EUR

EBITDA:

16252.6 Mio. EUR

Nettogewinn:

5961.82 Mio. EUR

Gewinn je Aktie:

2.93 EUR

Schulden:

39840.43 Mio. EUR

Liquide Mittel:

8628.33 Mio. EUR

Operativer Cashflow:

11964.22 Mio. EUR

Bargeldquote:

0.46

Umsatzwachstum:

-12.05%

Gewinnwachstum:

Dividende je Aktie:

2.13 EUR

Dividendenrendite:

4.1%

Dividendenschätzung:

4.15%

Div. Historie:

02.01.26 - 0.5355€
03.10.25 - 0.53196€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

BRISTOL-MYERS, BRISTOL MYERS

Letzte Datenerhebung:

18.02.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 2036.47 Mio. St.

Frei handelbar: 99.82%

Leerverk. Aktien: 1.47%

Rückkaufquote: -

Mitarbeiter: 32500

Umsatz/Mitarb.: 1.25 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: -1%

Bewertung:

KGV: 17.41

KGV lG: 9.8

KUV: 2.58

KBV: 6.64

PEG-Ratio: -

EV/EBITDA: 8.35

Rentabilität:

Bruttomarge: 65.89%

Gewinnmarge: 14.64%

Operative Marge: 31.36%

Managementeffizenz:

Gesamtkaprendite: 7.72%

Eigenkaprendite: 40.53%

>Anleihen

>Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>BRISTOL-MYERS Chart & Kurs - NYSE

>BRISTOL-MYERS News

17.02.26 - 23:33	Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) \| DelveInsight (PR Newswire)
	The juvenile idiopathic arthritis market is experiencing steady growth driven by rising disease awareness, improved diagnostic capabilities, and expanding access to advanced biologic therapies. Additionally, the launch of emerging therapies such as SOTYKTU (Bristol-Myers Squibb), BIMZELX......

17.02.26 - 20:18	Bristol Myers wins FDA priority review for multiple myeloma therapy (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 20:06	What Does the Market Think About Bristol-Myers Squibb Co? (Benzinga)
	Importance Rank: 1 read more...

11.02.26 - 23:33	EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) \| DelveInsight (PR Newswire)
	The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb),......

11.02.26 - 13:03	Bristol-Myers Squibb Company: Robert A. Winn Excellence in Clinical Trials Award Program Announces Third Cohort of Physician-Researchers for the Clinical Investigator Leadership Award (Accesswire)
	Bristol Myers Squibb Foundation is proud to support Conquer Cancer's EveryGrant and the American Heart Association to Advance Clinical Trials Leadership in Oncology and Cardiovascular ResearchOrigi......

06.02.26 - 00:09	Bristol-Myers Squibb outlines $46B–$47.5B 2026 revenue target as growth portfolio nears 60% of sales, driven by new product launches and pipeline catalysts (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.02.26 - 23:36	Why Bristol Myers Squibb Stock Topped the Market Today (Fool)
	At the end of last year, the company did particularly well with its lineup of newer medications....

05.02.26 - 18:15	Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates (Zacks)
	BMY beats Q4 earnings and revenue estimates as its Growth Portfolio jumps 16%, lifting shares despite continued declines in legacy drugs....

05.02.26 - 16:54

Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn’t Even Hit Yet (24/7 Wall St.)

Bristol Myers Squibb (NYSE:BMY) reported Q4 2025 revenue of $12.5 billion, essentially flat year-over-year, with full-year 2025 revenue reaching $48.2 billion. The pharmaceutical giant delivered non-GAAP EPS of $1.26 for the quarter, which included a $(0.60) impact from Orbital Therapeutics acquisition charges. The company announced results on Thursday, February 5, 2026, before market open. Growth ... Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn't Even Hit Yet The post Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn't Even Hit Yet appeared first on 24/7 Wall St.....

05.02.26 - 16:45	Bristol Myers (BMY) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
	Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....

05.02.26 - 16:00	Bristol Myers (BMY) Q4 2025 Earnings Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

05.02.26 - 16:00	Bristol Myers Squibb (BMY) Tops Q4 Earnings and Revenue Estimates (Zacks)
	Bristol Myers (BMY) delivered earnings and revenue surprises of +9.33% and +2.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...

05.02.26 - 15:48	Bristol-Myers Squibb übertrifft Prognosen für das vierte Quartal 2025 (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

05.02.26 - 13:49	ROUNDUP: Bristol-Myers Squibb Guides FY26 Above Estimates (AFX)
	NEW YORK CITY (dpa-AFX) - While reporting financial results for the fourth quarter on Thursday, Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings and revenue growth guidance for the f......

05.02.26 - 13:48	Bristol-Myers Squibb in charts: Q4 revenue from Eliquis, Opdivo, Yervoy, Orencia rises Y/Y; Sprycel and Pomalyst/ Imnovid falls (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.02.26 - 13:48	Bristol-Myers posts Q4 beat as growth portfolio offsets legacy headwinds (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.02.26 - 13:36	Bristol Myers Squibb Co. Reveals Rise In Q4 Profit (AFX)
	NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb Co. (BMY) reported a profit for its fourth quarter that Increases, from the same period last yearThe company's bottom line came in at $1.087 billion,......

05.02.26 - 13:12	Bristol Myers earnings beat estimates amid cancer immunotherapy drug strength (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

05.02.26 - 13:12	Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth (WSJ EN)
	Bristol Myers Squibb reported higher fourth-quarter revenue as growth in sales of its immuno-oncology treatments helped to offset a decline in revenue for some of its older drugs....

05.02.26 - 13:06	Bristol′s Outlook Tops Views as New Drugs Gain Momentum (Bloomberg)
	Bristol Myers Squibb Co. forecast 2026 sales and profit above Wall Street's expectations, a sign that the company's newer medicines are helping stem the losses from its older drugs that are losing patent protection....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Von allen Gütern ist das beste, ein edles Weib zu haben. - Euripides

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram